Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
NCT05585580Phase 2Active, not recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Mar 2023
- Primary completion
- Apr 2026
- Modality
- Immune Checkpoint Inhibitors, Cytokines & Interferons, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of serplulimab, lenvatinib, Paclitaxel Micelles for Injection in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Qilu Hospital of Shandong University. Started Mar 2023; status: active, not recruiting.
02
Drugs
serplulimablenvatinibPaclitaxel Micelles for Injection
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05585580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05585580.